 |
 |
|
North East and North Cumbria
ICS Formulary |
| Formulary Chapter 6: Endocrine system - Full Section
|
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
06.01 |
Drugs used in diabetes (0,0)
|
|
06.01.01 |
Insulins (0,0)
|
|
06.01.01.01 |
Short-acting insulins
(10,0)
|
|
|
Short-acting human insulin analogues (0,0)
|
|
06.01.01.02 |
Intermediate- and long-acting insulins
(8,0)
|
|
|
Biphasic insulins
(3,0)
|
|
06.01.01.03 |
Hypodermic equipment (0,0)
|
|
|
Needles (0,0)
|
|
|
Lancets (0,0)
|
|
06.01.02 |
Antidiabetic drugs (0,0)
|
|
06.01.02.01 |
Sulphonyureas
(4,0)
|
|
06.01.02.02 |
Biguanides
(1,0)
|
|
06.01.02.03 |
Other antidiabetic drugs
(1,0)
|
|
|
Alpha glucosidase inhibitors
(1,0)
|
|
|
DPP4 inhibitors (gliptins)
(4,0)
|
|
|
GLP1 agonists
(5,0)
|
|
|
Meglitinides (0,0)
|
|
|
SGL2 inhibitors
(5,0)
|
|
|
Thiazolidinediones
(1,0)
|
|
06.01.03 |
Diabetic ketoacidosis (0,0)
|
|
06.01.04 |
Treatment of hypoglycaemia
(5,0)
|
|
|
Chronic hypoglycaemia (0,0)
|
|
06.01.05 |
Treatment of diabetic nephropathy and neuropathy (0,0)
|
|
|
Diabetic nephropathy (0,0)
|
|
|
Diabetic neuropathy
(5,0)
|
|
06.01.06 |
Diagnostic and monitoring agents for diabetes mellitus (0,0)
|
|
|
Blood glucose monitoring
(6,0)
|
|
|
Urinalysis (0,0)
|
|
|
Oral glucose tolerance test (0,0)
|
|
|
Blood glucose meters for adults with type 2 diabetes (0,0)
|
|
|
Blood glucose meters for children and adults with type 1 diabetes (0,0)
|
|
|
Blood glucose meters for patients on continuous insulin infusion pump (0,0)
|
|
|
Blood glucose meters for patients with dexterity problems (0,0)
|
|
|
Talking blood glucose meters (0,0)
|
|
06.02 |
Thyroid and Antithyroid drugs (0,0)
|
|
06.02.01 |
Thyroid hormones
(3,0)
|
|
06.02.02 |
Antithyroid drugs
(6,0)
|
|
06.03 |
Corticosteroids (0,0)
|
|
06.03.01 |
Replacement therapy
(3,0)
|
|
06.03.02 |
Glucocorticoid therapy
(9,0)
|
|
|
Disadvantages of corticosteroids (0,0)
|
|
|
Use of corticosteroids (0,0)
|
|
|
Pregnancy and breastfeeding (0,0)
|
|
|
Administration (0,0)
|
|
|
Withdrawal of corticosteroids (0,0)
|
|
06.04 |
Sex hormones (0,0)
|
|
06.04.01 |
Female sex hormones and their modulators (0,0)
|
|
06.04.01.01 |
Oestrogens and Hormone Replacement Therapy HRT
(12,0)
|
|
|
Hormone replacement therapy (0,0)
|
|
|
Ethinylestradiol (0,0)
|
|
|
Raloxifene
(1,0)
|
|
|
Oestrogen only tablets (0,0)
|
|
|
Oestrogens and progestogen sequential combined therapy (0,0)
|
|
|
Continuous combined therapy (0,0)
|
|
|
Gonadomimetic (0,0)
|
|
|
Selective oestrogen modulator (0,0)
|
|
06.04.01.02 |
Progestogens
(7,0)
|
|
06.04.02 |
Male sex hormones and antagonists
(4,0)
|
|
|
Anti-androgens
(3,0)
|
|
06.04.03 |
Anabolic steroids (0,0)
|
|
06.04.04 |
Gender dysphoria
(13,0)
|
|
06.05 |
Hypothalamic and pituitary hormones and anti-oestrogens (0,0)
|
|
06.05.01 |
Hypothalamic and anterior pituitary hormones and anti-oestrogens
(1,0)
|
|
|
Anti-oestrogens
(1,0)
|
|
|
Anterior pituitary hormones
(10,0)
|
|
|
Hypothalmic hormones
(2,0)
|
|
06.05.02 |
Posterior pituitary hormones and antagonists
(1,0)
|
|
|
Posterior pituitary hormones
(3,0)
|
|
|
Antidiuretic hormone antagonists
(1,0)
|
|
06.06 |
Drugs affecting bone metabolism (0,0)
|
|
|
Osteoporosis (0,0)
|
|
06.06.01 |
Calcitonin and parathyroid hormone
(4,0)
|
|
06.06.02 |
Bisphosphonates and other drugs affecting bone metabolism
(1,0)
|
|
|
Bisphosphonates
(7,0)
|
|
|
Denosumab
(2,0)
|
|
|
Strontium renelate
(1,0)
|
|
|
Romosozumab
(1,0)
|
|
06.07 |
Other endocrine drugs
(3,0)
|
|
06.07.01 |
Bromocriptine and other dopaminergic drugs
(3,0)
|
|
06.07.02 |
Drugs affecting gonadotrophins
(9,0)
|
|
|
Gonadorelin analogues (0,0)
|
|
|
Breast pain (mastalgia) (0,0)
|
|
06.07.03 |
Metyrapone
(1,0)
|
|
06.07.04 |
Somatomedins
(1,0)
|
|
06.08 |
Metreleptin
(1,0)
|
|
|
|
